Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Exelixis, Inc. (EXEL)

16.79   -0.15 (-0.89%) 11-28 16:00
Open: 16.88 Pre. Close: 16.94
High: 16.965 Low: 16.69
Volume: 1,764,503 Market Cap: 5,416(M)

Technical analysis

as of: 2022-11-28 4:39:38 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 20.32     One year: 23.73
Support: Support1: 16.58    Support2: 16.07
Resistance: Resistance1: 17.39    Resistance2: 20.32
Pivot: 16.78
Moving Average: MA(5): 16.9     MA(20): 16.74
MA(100): 18.05     MA(250): 19.12
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 56.9     %D(3): 64.2
RSI: RSI(14): 51.7
52-week: High: 23.39  Low: 14.86
Average Vol(K): 3-Month: 2,297 (K)  10-Days: 1,452 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EXEL ] has closed below upper band by 49.0%. Bollinger Bands are 59.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 17 - 17.09 17.09 - 17.16
Low: 16.46 - 16.57 16.57 - 16.66
Close: 16.63 - 16.8 16.8 - 16.94

Company Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Headline News

Mon, 28 Nov 2022
Proposed off-leash dog park on outskirts of Kerikeri gets paws down from residents - Northern Advocate

Mon, 28 Nov 2022
Logistics Outsourcing Market demand and future scope with Russia-Ukraine Crisis Impact Analysis –Exel Logistics, Menlo Worldwide Logistics, FedEx, Ryder Logistics, Tibbett and Britten – Skegness Siren - Skegness Siren

Sun, 27 Nov 2022
THEN AND NOW: Recreating a classic photo of Maj. Rogers - BarrieToday

Sat, 26 Nov 2022
Madrid Magic for Wonderful Wandres - Fédération Equestre Internationale

Tue, 08 Nov 2022
Looking Into Exelixis's Return On Invested Capital - Exelixis (NASDAQ:EXEL) - Benzinga

Fri, 04 Nov 2022
"Chewing the gum, the walking" — Nick Van Exel on how Kobe Bryant went to extremes to imitate Michael Jordan - Basketball Network

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 323 (M)
Shares Float 317 (M)
% Held by Insiders 2.2 (%)
% Held by Institutions 88 (%)
Shares Short 9,500 (K)
Shares Short P.Month 9,060 (K)

Stock Financials

EPS 0.94
EPS Est Next Qtl 0.09
EPS Est This Year 0.28
EPS Est Next Year 0.67
Book Value (p.s.) 7.71
Profit Margin (%) 18.7
Operating Margin (%) 22.3
Return on Assets (ttm) 8.4
Return on Equity (ttm) 13.3
Qtrly Rev. Growth 25.3
Gross Profit (p.s.) 4.27
Sales Per Share 5.08
EBITDA (p.s.) 1.18
Qtrly Earnings Growth 89.4
Operating Cash Flow 385 (M)
Levered Free Cash Flow 306 (M)

Stock Valuations

PE Ratio 17.67
PEG Ratio 0.7
Price to Book value 2.17
Price to Sales 3.3
Price to Cash Flow 14.05

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.